Vera Therapeutics Inc.
Organization details
- Legal name
- Vera Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Brisbane
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- VERA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001831828
- EIN
- 81-2744449
Board of directors
-
Andrew Cheng · DirectorSince 2023
- Since 2023
-
Christopher Hite · DirectorSince 2026
- Since 2024
-
James R. Meyers · DirectorSince 2025
-
Kimball Hall · DirectorSince 2023
-
Maha Katabi · DirectorSince 2023
-
Marshall Fordyce · Director · PRESIDENT AND CEOSince 2023
-
Michael Morrissey · DirectorSince 2023
- Since 2023
- Since 2023
Chief executives
Director election results
Annual meeting of May 21, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
92.6%
-
99.7%
Board connections
9 of this board's directors also sit on 23 other boards. 22 are in the same sector.
-
Zenas BioPharma Inc. Same sectorvia Christy J. Oliger and Patrick G. Enright
-
Arbutus Biopharma Corporation Same sectorvia James R. Meyers
-
Atara Biotherapeutics Inc. Same sectorvia Beth C. Seidenberg
-
Bicara Therapeutics Inc. Same sectorvia Christy J. Oliger
-
BioAge Labs Inc. Same sectorvia Patrick G. Enright
-
Corvus Pharmaceuticals Inc. Same sectorvia Scott W. Morrison
-
CytomX Therapeutics Inc. Same sectorvia James R. Meyers
-
Damora Therapeutics Inc. Same sectorvia Andrew Cheng
-
Exelixis Inc. Same sectorvia Michael Morrissey
-
IDEAYA Biosciences Inc. Same sectorvia Scott W. Morrison
-
Jade Biosciences Inc. Same sectorvia Maha Katabi
-
Jazz Pharmaceuticals plc Same sectorvia Patrick G. Enright
-
Kailera Therapeutics Inc. Same sectorvia Christopher Hite
-
Karyopharm Therapeutics Inc. Same sectorvia Christy J. Oliger
-
Kyverna Therapeutics Inc. Same sectorvia Beth C. Seidenberg
-
Latigo Biotherapeutics Inc. Same sectorvia Beth C. Seidenberg
-
Progyny Inc. Same sectorvia Beth C. Seidenberg
-
Replimune Group Inc. Same sectorvia Christy J. Oliger
-
Sagimet Biosciences Inc. Same sectorvia Beth C. Seidenberg
- via Andrew Cheng
-
Tarsus Pharmaceuticals Inc. Same sectorvia Scott W. Morrison
-
Veradermics Incorporated Same sectorvia Patrick G. Enright
-
Zai Lab Limited Same sectorvia Scott W. Morrison
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $249,985
- 1 purchase by 1 insider
- Sold, last 12 months
- $8,550,122
- 24 sales by 8 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 15, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Option exercise | +18,500 | $2.90 | $53,650 |
| Sep 15, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Open-market sale | −18,500 | $37.00 | $684,500 |
| Sep 11, 2026 | Young Joseph R Officer (SVP, FINANCE, CHIEF ACCT OFFCR) | Option exercise | +5,000 | $3.94 | $19,700 |
| Sep 2, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Option exercise | +18,500 | $2.90 | $53,650 |
| Sep 2, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Open-market sale | −18,500 | $35.12 | $649,720 |
| Aug 3, 2026 | Boman Nancy Lee Officer (Chief Regulatory Officer) | Grant or award | +44,987 | — | — |
| Jul 7, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Open-market sale | −1,000 | $40.78 | $40,780 |
| Jul 7, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Open-market sale | −32,550 | $42.07 | $1,369,379 |
| Jul 7, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Open-market sale | −10,500 | $42.86 | $450,030 |
| Jul 7, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Open-market sale | −2,200 | $43.59 | $95,898 |
| Jun 23, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Open-market sale | −18,412 | $37.93 | $698,367 |
| Jun 23, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Open-market sale | −88 | $38.43 | $3,382 |
| May 12, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Open-market sale | −14,219 | $36.64 | $520,984 |
| May 12, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Open-market sale | −4,281 | $37.09 | $158,782 |
| Apr 14, 2026 | Marshall Fordyce Director, Officer (PRESIDENT AND CEO) | Open-market sale | −14,130 | $43.66 | $616,916 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Vera Therapeutics Inc.
Who is the CEO of Vera Therapeutics Inc.?
Marshall Fordyce is Vera Therapeutics Inc.'s President and CEO.
How many directors are on Vera Therapeutics Inc.'s board?
Vera Therapeutics Inc.'s board has 11 directors: Andrew Cheng, Beth C. Seidenberg, Christopher Hite, Christy J. Oliger, James R. Meyers, Kimball Hall, Maha Katabi, Marshall Fordyce, Michael Morrissey, Patrick G. Enright and 1 other.
Are Vera Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Vera Therapeutics Inc. insiders bought $249,985 of shares in 1 purchase and sold $8.6 million of shares in 24 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="vera-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.